Granite Investment Partners LLC Purchases 166,657 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Granite Investment Partners LLC increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 11.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,669,534 shares of the biopharmaceutical company's stock after purchasing an additional 166,657 shares during the quarter. Granite Investment Partners LLC owned 0.56% of Amicus Therapeutics worth $15,727,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in FOLD. XTX Topco Ltd acquired a new stake in Amicus Therapeutics in the 3rd quarter valued at about $405,000. Geode Capital Management LLC boosted its holdings in Amicus Therapeutics by 1.2% in the third quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company's stock valued at $70,499,000 after acquiring an additional 80,926 shares during the last quarter. Virtu Financial LLC acquired a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $107,000. Diversified Trust Co raised its stake in shares of Amicus Therapeutics by 9.7% in the 4th quarter. Diversified Trust Co now owns 81,758 shares of the biopharmaceutical company's stock valued at $770,000 after acquiring an additional 7,257 shares during the period. Finally, Park Avenue Securities LLC acquired a new position in shares of Amicus Therapeutics during the fourth quarter worth about $123,000.

Analysts Set New Price Targets

Several research firms recently issued reports on FOLD. Wells Fargo & Company cut their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, StockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $16.75.

Amicus Therapeutics Trading Up 1.9 %

FOLD traded up $0.13 during mid-day trading on Friday, reaching $6.83. The stock had a trading volume of 3,105,452 shares, compared to its average volume of 2,606,205. The stock has a market capitalization of $2.10 billion, a P/E ratio of -37.94, a P/E/G ratio of 1.51 and a beta of 0.79. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. Amicus Therapeutics, Inc. has a 52 week low of $6.20 and a 52 week high of $12.65. The firm's fifty day simple moving average is $8.48 and its two-hundred day simple moving average is $9.55.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.